Abstracts tagged "Knee"

Abstract Number: 2753 • 2013 ACR/ARHP Annual Meeting
Relationship Of Pre-Radiographic MRI Lesions With Prevalent Frequent Knee Symptoms and Incident Persistent Knee Symptoms In Persons At Higher Risk For Knee Osteoarthritis
Leena Sharma¹, Joan S. Chmiel¹, Orit Almagor¹, Dorothy D. Dunlop², Marc C. Hochberg³, Charles Eaton⁴, C. Kent Kwoh⁵, Rebecca D. Jackson⁶, Joan M. Bathon⁷, Ali Guermazi⁸, Frank Roemer⁹, Michel Crema⁸, W. Jerry Mysiw⁶ and Michael C. Nevitt¹⁰, ¹Northwestern University, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁴Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁵School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Ohio State University, Columbus, OH, ⁷Columbia University, New York, NY, ⁸Boston University, Boston, MA, ⁹Klinikum Augsburg, Augsburg, Germany, ¹⁰Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA
Background/Purpose: The clinical significance of pre-radiographic MRI lesions in persons at risk for knee OA is unclear. Understanding whether such lesions are inconsequential or early…
Abstract Number: 2146 • 2013 ACR/ARHP Annual Meeting
Effects Of Chondroitin Sulfate On Brain Response To Painful Stimulation In Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jordi Monfort¹, Jesús Pujol², O Contreras-Rodriguez², Jone Llorente-Onaindia², M López-Solà², Laura Blanco-Hinojo², J Deus², H Ortiz², Francisco Montañés³, M Campillo², Pere Benito², Laura Sánchez⁴, Marta Herrero⁵ and Josep Vergés⁶, ¹Reumatologia, Hospital del Mar, Barcelona, Spain, ²Hospital del Mar, Barcelona, Spain, ³Rhaumatology, Hospital del Mar, Barcelona, Spain, ⁴Bioiberica, Barcelona, Spain, ⁵Pharmascience Division, Bioiberica S.A., Barcelona, Spain, ⁶Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain
Background/Purpose: Knee osteoarthritis (OA) is a degenerative joint disease causing symptoms in 12% of people over the age of 65 . A variety of treatments…
Abstract Number: 265 • 2013 ACR/ARHP Annual Meeting
All-Cause Mortality and Incident Cardiovascular Disease In Knee Osteoarthritis: The Framingham Study
Devyani Misra¹, David T. Felson², Ida K. Haugen³, Martin Englund⁴ and Tuhina Neogi¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: Studies examining the relation of osteoarthritis (OA) to mortality or cardiovascular disease (CVD) have reported conflicting results, raising the question of whether OA itself…
Abstract Number: 2754 • 2013 ACR/ARHP Annual Meeting
Trajectory Of Cartilage Thickness Change During The Years Prior To Knee Replacement: Data From The Osteoarthritis Initiative
Felix Eckstein¹, Robert M. Boudreau², Zhijie Wang³, Michael J. Hannon³, Wolfgang Wirth¹, Sebastian Cotofana⁴, Ali Guermazi⁵, Frank Roemer⁶, Michael C. Nevitt⁷, Markus John⁸, Christoph Ladel⁹, David J. Hunter¹⁰ and C. Kent Kwoh¹¹, ¹Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ²Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Musculoskeletal Anatomy, Paracelsus Medical University, Salzburg, Austria, ⁵Boston University, Boston, MA, ⁶Klinikum Augsburg, Augsburg, Germany, ⁷Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Merck KG, Darmstadt, Germany, ¹⁰Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹¹School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Knee replacement (KR) represents a clinically important and cost-effective endpoint of knee osteoarthritis (OA). We have shown previously that, in a year prior to…
Abstract Number: 2148 • 2013 ACR/ARHP Annual Meeting
Use Of Low Dose Aspirin Is Associated With Reduced Medial Tibial Cartilage Loss In Symptomatic Osteoarthritis: DATA From A Cohort Study
Anita Wluka¹, Changhai Ding², Yuanyuan Wang³, Graeme Jones⁴, Andrew Teichtahl⁵ and Flavia Cicuttini¹, ¹Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ²Musculoskeletal Unit, Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia, ³Monash University, Melbourne, Australia, ⁴Menzies Research Institute Tasmania, University of Tasmania, HOBART, Australia, ⁵Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Background/Purpose: Inflammation and vascular disease have recently been shown to play a role in the pathogenesis of osteoarthritis (OA). Low dose aspirin is commonly used…
Abstract Number: 266 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Disease In Osteoarthritis: Hip Versus Knee and The Influence Of Multiple Symptomatic Joint Involvement
Anthony V. Perruccio¹, Rita A. Kandel² and Aileen M. Davis³, ¹Toronto Western Hospital, Toronto Western Research Institute, and University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ³Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: The strength of association between obesity and osteoarthritis (OA) is reported to vary by joint (e.g. stronger association with knee than hip). As well,…
Abstract Number: 2755 • 2013 ACR/ARHP Annual Meeting
The Clinical Significance and Natural History Of Knee Bone Marrow Lesions Over 8 Years
Yi Chao Foong¹, Hussain Ijaz Khan¹, Dawn Aitken¹, Changhai Ding², Flavia Cicuttini³ and Graeme Jones², ¹Musculoskeletal Unit, Menzies Research Institute Tasmania, University of Tasmania, Hobart, 7000, Australia, ²Musculoskeletal Unit, Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia, ³Department of Epidemiology and Preventive Medicine, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 3004, Australia
Background/Purpose: There is increasing evidence to suggest that bone marrow lesions (BMLs) play a key role in the pathogenesis of OA. Whilst many studies have…
Abstract Number: 2111 • 2013 ACR/ARHP Annual Meeting
The Impact Of Centralized Pain On Long-Term Analgesic Response To Lower Extremity Joint Arthroplasty: A Prospective, Observational Cohort Study
Chad M. Brummett¹, Andrew Urquhart², Brian Hallstrom², Alex Tsodikov³, David A. Williams⁴ and Daniel J. Clauw⁵, ¹Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, ²Orthopedics, University of Michigan Health System, Ann Arbor, MI, ³Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, ⁴Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI, ⁵Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI
Background/Purpose : In cross-sectional studies, depression and pain in other locations have been reported as predicting poorer outcomes following total knee and hip arthroplasty. These…
Abstract Number: 244 • 2013 ACR/ARHP Annual Meeting
Association Between Serum Adipokine Levels and Extent Of Symptomatic Joint Involvement In Hip and Knee Osteoarthritis
Anthony V. Perruccio¹, Vinod Chandran², Nizar N. Mahomed³ and Rajiv Gandhi⁴, ¹Toronto Western Hospital, Toronto Western Research Institute, and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Orthopaedic Surgery, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Arthritis Program, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) has not traditionally been considered a systemic joint disease. However, a growing body of evidence suggests that OA cannot solely be accounted…
Abstract Number: 2668 • 2013 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Dose Ranging Study Comparing FX006, An Intra-Articular (IA) Sustained-Release Formulation Of Triamcinolone Acetonide (TCA), To An Approved Injectable Suspension Of TCA In Patients With Osteoarthritis (OA) Of The Knee
Neil Bodick¹, Joelle Lufkin¹, Christina Willwerth¹, Pierre Lachance², Gregory Jasey³, Anil Gupta⁴, Anthony Chris⁵, Marc Russo⁶, Michael O'Mahony⁷, Sam Henein⁸, Louise Murdoch⁹, Ferdinandus de Looze¹⁰, David Hunter¹¹ and Michael Clayman¹, ¹Flexion Therapeutics, Burlington, MA, ²Clinique St-Louis (Recherche) Inc, Quebec, QC, Canada, ³North Walkerville Orthopaedic Associates, Windsor, ON, Canada, ⁴Anil K. Gupta Medicine Professional Corporation, Toronto, ON, Canada, ⁵Aim Health Group, Waterloo, ON, Canada, ⁶Hunter Clinical Research, Broadmeadow, Australia, ⁷London Road Diagnostic Clinic and Medical Centre, Sarnia, ON, Canada, ⁸SKDS Research Inc., Newmarket, ON, Canada, ⁹Emeritus Research, Malvern East, Australia, ¹⁰AusTrials Pty Limited, Sherwood, Australia, ¹¹Royal North Shore Hospital, St. Leonards, Australia
Background/Purpose: FX006 is a novel sustained-release formulation of TCA in poly(lactic-co-glycolic) acid microspheres intended to maintain therapeutic concentrations in the joint up to 3 months…
Abstract Number: 2112 • 2013 ACR/ARHP Annual Meeting
Hip and Knee Arthroplasty In Patients With Rheumatoid Arthritis: Results From The Australian Orthopaedic Association National Joint Replacement Registry: 2003 To 2011
Andrew Lim¹, Stephen Graves², Yen Liu², Lionel Schachna¹ and Russell R. Buchanan¹, ¹Rheumatology, Austin Health, Melbourne, Australia, ²Australian Orthopaedic Association National Joint Replacement Registry, Adelaide, Australia
Background/Purpose: Total Joint Replacement in rheumatoid arthritis (RA) patients is a marker of disease severity. Whilst the rate of total hip (THA) and total knee…
Abstract Number: 247 • 2013 ACR/ARHP Annual Meeting
Associations Between Levels Of Urinary C-Telopeptide Fragments Of Type II Collagen and Knee Structure In Asymptomatic Middle-Aged Women
Binghui Wang¹, Hans Kurniawan Pramono², Flavia Cicuttini³, Anita Wluka³, Fahad Hanna², Susan Davis², Robin Bell², Andrew Teichtahl¹ and Yuanyuan Wang², ¹Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ²Monash University, Melbourne, Australia, ³Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
Background/Purpose: There is evidence for an association between levels of urinary C-telopeptide fragments of type II collagen (uCTX-II) and the risk of knee osteoarthritis. The…
Abstract Number: 2669 • 2013 ACR/ARHP Annual Meeting
Treatment Of Knee Osteoarthritis Patients With Strontium Ranelate Reduces The Loss Of Cartilage Volume and Bone Marrow Lesions As Assessed By Magnetic Resonance Imaging: Data From The Phase III Strontium Ranelate Efficacy In Knee Osteoarthrtis Trial
Johanne Martel-Pelletier¹, Camille Roubille¹, Jean-Pierre Raynauld¹, François Abram², Marc Dorais³, Philippe Delorme¹ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³StatSciences Inc., Notre-Dame de l’Île Perrot, QC, Canada
Background/Purpose: This study aimed to evaluate in a subpopulation of osteoarthritis (OA) patients from the SEKOIA Phase III trial the disease-modifying (DMOAD) effect of strontium…
Abstract Number: 2119 • 2013 ACR/ARHP Annual Meeting
Higher Mortality In Males Compared To Females Undergoing Total Knee Or Total Hip Arthroplasty: A Study Of National Time Trends, 2003-2010
Jasvinder A. Singh^1,2 and Rekha Ramachandaran³, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess the time-trends in gender differences in mortality after primary total knee and total hip arthroplasty (TKA and THA) by rural or urban…
Abstract Number: 250 • 2013 ACR/ARHP Annual Meeting
Synovial Inflammation In Meniscal Tear Patients: CCL19 mRNA Expression Is Independently Associated With Knee Related Disability
Anjali Nair¹, Charles Bush-Joseph², Nikhil Verma², Matthew Tetreault², Kanta Saha³, Arkady Margulis⁴, Louis F. Fogg⁵ and Carla R. Scanzello³, ¹Section of Rheumatology, Rush University Medical Center, Chicago, IL, ²Orthopedics, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL, ⁵Department of Nursing, Rush University Medical Center, Chicago, IL
Background/Purpose: In patients with knee osteoarthritis (OA), synovitis is associated with severity of knee symptoms. Previously, we demonstrated that in patients undergoing partial meniscectomy without…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.